Brittany Stout, NP
Payments from drug & device makers
Across 162 payments — averaging $14.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$490
- Novo Nordisk$275
- AstraZeneca$137
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$130
- GSK$130
- Lilly USA, LLC$123
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,39899%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 51 | $490 |
| Novo Nordisk | 11 | $275 |
| AstraZeneca | 9 | $137 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $130 |
| GSK | 8 | $130 |
| Lilly USA, LLC | 8 | $123 |
| Alkermes, Inc. | 6 | $114 |
| Axsome Therapeutics, Inc. | 4 | $101 |
| Idorsia Pharmaceuticals US Inc | 6 | $100 |
| Indivior Inc. | 5 | $86 |
| Amgen | 5 | $77 |
| Pfizer | 4 | $73 |
| Ironshore Pharmaceuticals Inc. | 3 | $59 |
| Lundbeck LLC | 3 | $56 |
| Corium, LLC | 6 | $54 |
| Boehringer Ingelheim | 3 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Eisai Inc. | 2 | $32 |
| Bayer | 2 | $29 |
| Pear Therapeutics (US), Inc. | 2 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Exact Sciences | 1 | $21 |
| Abbott | 1 | $18 |
| Mylan Specialty L.p. | 1 | $15 |
| Organon | 1 | $12 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$125
How this compares
$2,422 in reported general payments places this provider in the 80th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 88 | $99,376 |
| FarxigaDapagliflozin Propanediol | 60 | $57,490 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $54,715 |
| JardianceEmpagliflozin | 38 | $54,649 |
| RexultiBrexpiprazole | 34 | $50,470 |
| TrulicityDulaglutide | 34 | $41,310 |
| EliquisApixaban | 33 | $40,139 |
| XareltoRivaroxaban | 43 | $33,821 |
| MounjaroTirzepatide | 16 | $27,687 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $24,132 |
| JanuviaSitagliptin Phosphate | 21 | $22,138 |
| Repatha SureclickEvolocumab | 22 | $22,020 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $13,542 |
| LinzessLinaclotide | 17 | $13,304 |
| TradjentaLinagliptin | 14 | $12,399 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $275 | $99,37688 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta, Synjardy | $38 | $87,86782 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $130 | $72,25188 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Olanzapine | $123 | $70,35583 claims |
| AstraZenecaFarxiga | $137 | $57,49060 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $37 | $50,47034 claims |
| PfizerEliquis | $73 | $40,13933 claims |
| AbbVieLinzess, Synthroid | $490 | $14,87535 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $100 | $8,97118 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $37 | $5,33714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,392 family providers in Indiana.
Other family in Paoli
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.